insights_auto
Perché 500124 è in calo 2,06%?
Approfondiscichevron_right
500124:BOM
Dr. Reddy's Laboratories
1.214,10 INR
arrow_downward
-2,06%(-25,55) 1G
14 ott, 15:53:17 GMT+5:30 · INR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per 500124 in corso…
Apertura
1.237,35 INR
Massimo
1.237,35 INR
Minimo
1.209,65 INR
Cap. mercato
1,01 Bln
Vol. medio
85,80K
Volume
43,85K
Dividendo
0,66%
Dividendo trimestrale
2,00 INR
Data di stacco dividendo
10 lug 2026
Rapporto P/E
31,40
Max 52 sett.
1.414,40 INR
Min 52 sett.
1.080,05 INR
Utili per azione
38,67 INR
Azioni in circolazione
166,06 Mln
N. di dipendenti
28K
Apertura
1.237,35 INR
Massimo
1.237,35 INR
Minimo
1.209,65 INR
Cap. mercato
1,01 Bln
Vol. medio
85,80K
Volume
43,85K
Dividendo
0,66%
Dividendo trimestrale
2,00 INR
Data di stacco dividendo
10 lug 2026
Rapporto P/E
31,40
Max 52 sett.
1.414,40 INR
Min 52 sett.
1.080,05 INR
Utili per azione
38,67 INR
Azioni in circolazione
166,06 Mln
N. di dipendenti
28K
Articoli giornalistici
Da fonti web e partner giornalistici
TipRanks
·
Meno di un minuto fa
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
www.marketscreener.com
·
1 giorno fa
Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
Profilo
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Informazioni su Dr. Reddy's Laboratories
CEOErez Israeli
Dipendenti27,5K
Data di fondazione1984
SedeHyderabad, Andhra Pradesh, India
Settore-
Sito webdrreddys.com